Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/24778
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12494]
Metadata
Show full item record
AN α-GAL-CONTAINING NEOGLYCOPROTEIN-BASED VACCINE PARTIALLY PROTECTS AGAINST MURINE CUTANEOUS LEISHMANIASIS CAUSED BY LEISHMANIA MAJOR
Author
Affilliation
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular e Doenças Endêmicas. Rio de Janeiro, RJ. Brasil.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom / Liverpool School of Tropical Medicine. Department of Vector Biology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular e Doenças Endêmicas. Rio de Janeiro, RJ. Brasil.
Liverpool School of Tropical Medicine. Department of Parasitology. Pembroke Place, Liverpool, United Kingdom / Liverpool School of Tropical Medicine. Department of Vector Biology. Pembroke Place, Liverpool, United Kingdom.
University of Texas at El Paso. Department of Chemistry. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
University of Texas at El Paso. Department of Biological Sciences. Border Biomedical Research Center. El Paso, Texas, USA.
Abstract
Protozoan parasites from the genus Leishmania cause broad clinical manifestations known as leishmaniases, which affect millions of people worldwide. Cutaneous leishmaniasis (CL), caused by L. major, is one the most common forms of the disease in the Old World. There is no preventive or therapeutic human vaccine available for L. major CL, and existing drug treatments are expensive, have toxic side effects, and resistant parasite strains have been reported. Hence, further therapeutic interventions against the disease are necessary. Terminal, non-reducing, and linear α-galactopyranosyl (α-Gal) epitopes are abundantly found on the plasma membrane glycolipids of L. major known as glycoinositolphospholipids. The absence of these α-Gal epitopes in human cells makes these glycans highly immunogenic and thus potential targets for vaccine development against CL.
Share